Phase1 may demonstrate target engagement, page-23

The last PBT2 remarks from the 2017 annual report were "Following the Company’s review of its development programs, further development of PBT2 will remain on hold." from the chairman's letter. Further into the report regarding PBT2 development "Given the safety and efficacy data to date with PBT2, Prana is reviewing its options to either undertake additional non-clinical studies in the dog, development opportunities at dosing levels permitted by the FDA and/or alternative therapeutic applications of PBT2 that require shorter terms of administration."

Now this is interesting. In the IP section of the report: " Also in the last 12 months, a case has transitioned from a Provisional application to new PCT patent application, directed to a new use for PBT2 that is not a neurodegenerative disease."

I hope they remember what was said in the Dec 2016 update "the use of PBT2 at lower doses (as currently permitted by the FDA), or using PBT2 for acute indications requiring shorter term use, all with the aim of realising shareholder value from this part of its IP portfolio."